comparemela.com

Latest Breaking News On - Molnupiravir covid - Page 1 : comparemela.com

Merck Q1 2023 Report Shows Revenue Drop as COVID Treatment Sales Crash, MRK Stock Down 1%

Affected by reduced demand for Covid drug Molnupiravir, Merck has published reduced revenue figures according to its Q1 2023 report.

Molnupiravir Covid antiviral treatment hastens recovery - trial

vimarsana © 2020. All Rights Reserved.